| Literature DB >> 27190518 |
K Chishimba1, B M Hang'ombe2, K Muzandu2, S E Mshana3, M I Matee4, C Nakajima5, Y Suzuki5.
Abstract
The frequent administering of antibiotics in the treatment of poultry diseases may contribute to emergence of antimicrobial-resistant strains. The objective of this study was to detect the presence of extended-spectrum β-lactamase- (ESBL-) producing Escherichia coli in poultry in Zambia. A total of 384 poultry samples were collected and analyzed for ESBL-producing Escherichia coli. The cultured E. coli isolates were subjected to antimicrobial susceptibility tests and the polymerase chain reaction for detection of bla CTX-M, bla SHV, and bla TEM genes. Overall 20.1%, 77/384, (95% CI; 43.2-65.5%) of total samples analyzed contained ESBL-producing Escherichia coli. The antimicrobial sensitivity test revealed that 85.7% (66/77; CI: 75.7-92) of ESBL-producing E. coli isolates conferred resistance to beta-lactam and other antimicrobial agents. These results indicate that poultry is a potential reservoir for ESBL-producing Escherichia coli. The presence of ESBL-producing Escherichia coli in poultry destined for human consumption requires strengthening of the antibiotic administering policy. This is important as antibiotic administration in food animals is gaining momentum for improved animal productivity in developing countries such as Zambia.Entities:
Year: 2016 PMID: 27190518 PMCID: PMC4852107 DOI: 10.1155/2016/5275724
Source DB: PubMed Journal: Int J Microbiol
Confirmed ESBL-producing E. coli (using PCR and gene detection) isolates.
| Detected gene (s) | Number of | % of |
|---|---|---|
| SHV | 2 | 0.52 |
| CTX-M | 50 | 13 |
| TEM | 3 | 0.8 |
| CTX-M and TEM | 17 | 4.4 |
| CTX-M and SHV | 2 | 0.52 |
| TEM and SHV | 1 | 0.3 |
| CTX-M, SHV, and TEM | 2 | 0.52 |
| Noneb | 307 | 79.9 |
| Proven ESBL producers | 77 | 20.1 |
a384 E. coli isolates suspected of being ESBL producers were examined.
bNegative in all PCRs.
Antibiotic susceptibilities of the isolates n = 77.
| Antibiotic | Resistant number (%) |
|---|---|
| Cefotaxime/ceftazidime | 77 (100%) |
| Ampicillin | 77 (100%) |
| Chloramphenicol | 44 (57.1%) |
| Ciprofloxacin | 37 (48.1%) |
| Gentamicin | 29 (37.7%) |
| Nalidixic acid | 37 (48.1%) |
| Norfloxacin | 42 (54.5%) |
| Streptomycin | 15 (20.8%) |
| Sulfamethoxazole/trimethoprim | 32 (41.6%) |
| Tetracycline | 46 (59.7%) |
Antibiotic resistance patterns of E. coli isolates.
| Antibiotic combination | Number of resistant isolates | % | Observation |
|---|---|---|---|
| Ampicillin and tetracycline | 1 | 1.3 | Resistant to two antibiotics |
|
| |||
| Ampicillin, tetracycline, chloramphenicol, and ceftazidime | 3 | 3.9 | Resistant to four antibiotics |
|
| |||
| Ampicillin, ceftazidime, chloramphenicol, and norfloxacin | 3 | 3.9 | Resistant to four antibiotics |
|
| |||
| Ampicillin, chloramphenicol, cefotaxime, and sulfamethoxazole | 3 | 3.9 | Resistant to four antibiotics |
|
| |||
| Ampicillin, streptomycin, gentamicin, tetracycline, and cefotaxime | 9 | 11.7 | Resistant to five antibiotics |
|
| |||
| Ampicillin, streptomycin, tetracycline, cefotaxime, nalidixic acid, ceftazidime, norfloxacin, and ciprofloxacin | 35 | 45.5 | Resistant to six antibiotics |